Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:1
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [31] Prediction tools in non-muscle invasive bladder cancer
    Zamboni, Stefania
    Moschini, Marco
    Simeone, Claudio
    Antonelli, Alessandro
    Mattei, Agostino
    Baumeister, Philipp
    Xylinas, Evanguelos
    Hakenberg, Oliver W.
    Aziz, Atiqullah
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 (01) : 39 - 45
  • [32] Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer
    Smani, Shayan
    Dubois, Julien
    Zhao, Kai
    Sutherland, Ryan
    Rahman, Syed N.
    Humphrey, Peter
    Hesse, David
    Tan, Wei Shen
    Martin, Darryl
    Lokeshwar, Soum D.
    Ghali, Fady
    CURRENT ONCOLOGY REPORTS, 2025, : 236 - 246
  • [33] The Costs of Non-Muscle Invasive Bladder Cancer
    James, Andrew C.
    Gore, John L.
    UROLOGIC CLINICS OF NORTH AMERICA, 2013, 40 (02) : 261 - +
  • [34] Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
    You, Chengyu
    Li, Xianhui
    Du, Yuelin
    Wang, Hui
    Zhang, Xiaojun
    Wei, Tangqiang
    Wang, Anguo
    PEERJ, 2021, 9
  • [35] Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer
    Popli, Swati
    Durant, Adri M.
    Tyson, Mark
    Singh, Parminder
    CURRENT ONCOLOGY REPORTS, 2025,
  • [36] Hyperthermia for non-muscle invasive bladder cancer
    Soria, Francesco
    Allasia, Marco
    Oderda, Marco
    Gontero, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (03) : 313 - 321
  • [37] ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer
    Leonardo L. Monteiro
    J. Alfred Witjes
    Piyush K. Agarwal
    Christopher B. Anderson
    Trinity J. Bivalacqua
    Bernard H. Bochner
    Joost L. Boormans
    Sam S. Chang
    Jose L. Domínguez-Escrig
    James M. McKiernan
    Colin Dinney
    Guilherme Godoy
    Girish S. Kulkarni
    Paramananthan Mariappan
    Michael A. O’Donnell
    Cyrill A. Rentsch
    Jay B. Shah
    Eduardo Solsona
    Robert S. Svatek
    Antoine G. van der Heijden
    F. Johannes P. van Valenberg
    Wassim Kassouf
    World Journal of Urology, 2019, 37 : 51 - 60
  • [38] Apaziquone for non-muscle invasive bladder cancer: a critical review
    Witjes, J. Alfred
    Kolli, Prasad S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1085 - 1096
  • [39] Review on gender differences in non-muscle invasive bladder cancer
    Bilski, Konrad
    Zapala, Lukasz
    Skrzypczyk, Michal A.
    Oszczudlowski, Maciej
    Dobruch, Jakub
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 (01) : 12 - 20
  • [40] Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer
    Barlow, LaMont J.
    Benson, Mitchell C.
    CURRENT UROLOGY REPORTS, 2013, 14 (02) : 65 - 70